593
Views
25
CrossRef citations to date
0
Altmetric
Brief Report

Val66Met polymorphism association with serum BDNF and inflammatory biomarkers in major depression

, , , , , , , & show all
Pages 402-409 | Received 20 Apr 2017, Accepted 22 Jun 2017, Published online: 12 Jul 2017

References

  • Amorim P. 2000. Mini International Neuropsychiatric Interview (MINI): validation of a short structured diagnostic psychiatric interview. Rev Bras Psiquiatr. 22:106–115.
  • Anisman H, Hayley S. 2012. Inflammatory factors contribute to depression and its comorbid conditions. Sci Signal. 5:pe45–pe45.
  • Audet M-C, Anisman H. 2013. Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses. Front Cell Neurosci. 7:68.
  • Autry AE, Monteggia LM. 2012. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 64:238–258.
  • Bus BAA, Arias-Vasquez A, Franke B, Prickaerts J, de Graaf J, Voshaar RCO. 2012. Increase in serum brain-derived neurotrophic factor in met allele carriers of the BDNF Val66Met polymorphism is specific to males. Neuropsychobiology. 65:183–187.
  • Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. 2014. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci. 8:430.
  • Cassano P, Bui E, Rogers AH, Walton ZE, Ross R, Zeng M, Nadal-Vicens M, Mischoulon D, Baker AW, Keshaviah A, et al. 2017. Inflammatory cytokines in major depressive disorder: a case-control study. Aust N Z J Psychiatry. 51:23–31.
  • Chen Z-Y, Bath K, McEwen B, Hempstead B, Lee F. 2008. Impact of genetic variant BDNF (Val66Met) on brain structure and function. Novartis Found Symp. 289:180–188. Discussion 188–195.
  • Dooley LN, Ganz PA, Cole SW, Crespi CM, Bower JE. 2016. Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. J Affect Disord. 197:43–50.
  • Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. 2010. A meta-analysis of cytokines in major depression. Biol Psychiatry. 67:446–457.
  • D’Sa C, Duman RS. 2002. Antidepressants and neuroplasticity. Bipolar Disord. 4:183–194.
  • Duman RS. 2014. Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci. 16:11–27.
  • Duman RS, Aghajanian GK. 2012. Synaptic dysfunction in depression: potential therapeutic targets. Science. 338:68–72.
  • Duman RS, Malberg J, Nakagawa S, D’Sa C. 2000. Neuronal plasticity and survival in mood disorders. Biol. Psychiatry. 48:732–739.
  • Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, et al. 2003. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 112:257–269.
  • Elzinga BM, Molendijk ML, Oude Voshaar RC, Bus BAA, Prickaerts J, Spinhoven P, Penninx BJWH. 2011. The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met. Psychopharmacology (Berl). 214:319–328.
  • Gawali NB, Bulani VD, Chowdhury AA, Deshpande PS, Nagmoti DM, Juvekar AR. 2016. Agmatine ameliorates lipopolysaccharide induced depressive-like behaviour in mice by targeting the underlying inflammatory and oxido-nitrosative mediators. Pharmacol Biochem Behav. 149:1–8.
  • Ge L, Liu L, Liu H, Liu S, Xue H, Wang X, Yuan L, Wang Z, Liu D. 2015. Resveratrol abrogates lipopolysaccharide-induced depressive-like behavior, neuroinflammatory response, and CREB/BDNF signaling in mice. Eur J Pharmacol. 768:49–57.
  • Gibney SM, McGuinness B, Prendergast C, Harkin A, Connor TJ. 2013. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun. 28:170–181.
  • González-Giraldo Y, Camargo A, López-León S, Forero DA. 2015. No association of BDNF, COMT, MAOA, SLC6A3, and SLC6A4 genes and depressive symptoms in a sample of healthy colombian subjects. Depress Res Treat. 2015:145483.
  • Grande I, Magalhães PVS, Chendo I, Stertz L, Fries GR, Cereser KM, Cunha ÂBM, Gói P, Kunz M, Udina M, et al. 2014. Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: an open-label trial. Acta Psychiatr Scand. 129:393–400.
  • Groves JO. 2007. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry. 12:1079–1088.
  • Guan Z, Fang J. 2006. Peripheral immune activation by lipopolysaccharide decreases neurotrophins in the cortex and hippocampus in rats. Brain Behav Immun. 20:64–71.
  • Guo J, Lin P, Zhao X, Zhang J, Wei X, Wang Q, Wang C. 2014. Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice. Neuroscience. 263:1–14.
  • Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. 2015. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 49:206–215.
  • Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 6:278–296.
  • Hosang GM, Shiles C, Tansey KE, McGuffin P, Uher R. 2014. Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis. BMC Med. 12:7.
  • Jamal M, Van der Does W, Elzinga BM, Molendijk ML, Penninx BWJH. 2015. Association between smoking, nicotine dependence, and BDNF Val66Met polymorphism with BDNF concentrations in serum. Nicotine Tob Res. 17:323–329.
  • Kenis G, Prickaerts J, van Os J, Koek GH, Robaeys G, Steinbusch HWM, Wichers M. 2011. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor? Int J Neuropsychopharmacol. 14:247–253.
  • Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, et al. 2017. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatrica Scandinavica. 135:373–387.
  • Lang UE, Hellweg R, Sander T, Gallinat J. 2009. The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry. 14:120–122.
  • Lapchak PA, Araujo DM, Hefti F. 1993. Systemic interleukin-1 beta decreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation. Neuroscience. 53:297–301.
  • Linn BS, Linn MW, Gurel L. 1968. Cumulative illness rating scale. J Am Geriatr Soc. 16:622–626.
  • Liu Y, Ho RC-M, Mak A. 2012. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 139:230–239.
  • Lotrich FE, Albusaysi S, Ferrell RE. 2013. Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment. Neuropsychopharmacology. 38:985–995.
  • Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, Ruberto A, Tatarelli R, Nicoletti F, Girardi P, et al. 2009. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res. 43:247–254.
  • Miller AH, Raison CL. 2016. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 16:22–34.
  • Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF. 1992. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 41:237–248.
  • Molendijk ML, Bus BAA, Spinhoven P, Penninx BWJH, Kenis G, Prickaerts J, Voshaar RCO, Elzinga BM. 2011. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry. 16:1088–1095.
  • Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BWJH, Elzinga BM. 2014. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry. 19:791–800.
  • Moreira FP, Fabião JD, Bittencourt G, Wiener CD, Jansen K, Oses JP, Quevedo L, de Á, Souza LDM, Crispim D, Portela LV, et al. 2015. The Met allele of BDNF Val66Met polymorphism is associated with increased BDNF levels in generalized anxiety disorder. Psychiatr Genet. 25:201–207.
  • Neto FL, Borges G, Torres-Sanchez S, Mico JA, Berrocoso E. 2011. Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Curr Neuropharmacol. 9:530–552.
  • Numakawa T, Richards M, Nakajima S, Adachi N, Furuta M, Odaka H, Kunugi H. 2014. The role of brain-derived neurotrophic factor in comorbid depression: possible linkage with steroid hormones, cytokines, and nutrition. Front Psychiatry. 5:136.
  • Ozan E, Okur H, Eker Ç, Eker ÖD, Gönül AS, Akarsu N. 2010. The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels. Brain Res Bull. 81:61–65.
  • Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, Pi B, Thurmond L, Bilello JA. 2013. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol. Psychiatry. 18:332–339.
  • Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SDJ. 2003. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA. 100:177–182.
  • Patas K, Penninx BWJH, Bus BAA, Vogelzangs N, Molendijk ML, Elzinga BM, Bosker FJ, Oude Voshaar RC. 2014. Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features. Brain Behav Immun. 36:71–79.
  • Pivac N, Kim B, Nedić G, Joo YH, Kozarić-Kovacić D, Hong JP, Muck-Seler D. 2009. Ethnic differences in brain-derived neurotrophic factor Val66Met polymorphism in Croatian and Korean healthy participants. Croat Med J. 50:43–48.
  • Ribeiro L, Busnello JV, Cantor RM, Whelan F, Whittaker P, Deloukas P, Wong M-L, Licinio J. 2007. The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. Neuroreport. 18:1291–1293.
  • Şahin TD, Karson A, Balcı F, Yazır Y, Bayramgürler D, Utkan T. 2015. TNF-alpha inhibition prevents cognitive decline and maintains hippocampal BDNF levels in the unpredictable chronic mild stress rat model of depression. Behav Brain Res. 292:233–240.
  • Sánchez-Mora C, Ribasés M, Ramos-Quiroga JA, Casas M, Bosch R, Boreatti-Hümmer A, Heine M, Jacob CP, Lesch K-P, Fasmer OB, et al. 2010. Meta-analysis of brain-derived neurotrophic factor p.Val66Met in adult ADHD in four European populations. Am J Med Genet B Neuropsychiatr Genet. 153B:512–523.
  • Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, Schulze TG, Deschner M, Schmäl C, Höfels S, et al. 2005. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry. 58:307–314.
  • Sen S, Duman R, Sanacora G. 2008. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 64:527–532.
  • Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. 2001. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29:308–311.
  • Spanemberg L, Caldieraro M, Arrua Vares E, Wollenhaupt de Aguiar B, Yuri Kawamoto S, Parker G, Pio Fleck M, Kauer-Sant’Anna M, Galvao E. 2014. Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure. Neuropsychiatr Dis Treat. 10:1523–1531.
  • Surtees PG, Wainwright NWJ, Willis-Owen SAG, Sandhu MS, Luben R, Day NE, Flint J. 2007. No association between the BDNF Val66Met polymorphism and mood status in a non-clinical community sample of 7389 older adults. J Psychiatr Res. 41:404–409.
  • Terracciano A, Piras MG, Lobina M, Mulas A, Meirelles O, Sutin AR, Chan W, Sanna S, Uda M, Crisponi L, et al. 2013. Genetics of serum BDNF: meta-analysis of the Val66Met and genome-wide association study. World J Biol Psychiatry. 14:583–589.
  • Tramontina J, Frey BN, Andreazza AC, Zandona M, Santin A, Kapczinski F. 2007. Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Mol Psychiatry. 12:230–231.
  • Verhagen M, van der Meij A, van Deurzen PAM, Janzing JGE, Arias-Vásquez A, Buitelaar JK, Franke B. 2010. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry. 15:260–271.
  • Vinberg M, Bukh JD, Bennike B, Kessing LV. 2013. Are variations in whole blood BDNF level associated with the BDNF Val66Met polymorphism in patients with first episode depression? Psychiatry Res. 210:102–108.
  • Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J. 2009. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry. 33:722–726.
  • Zhang J-C, Yao W, Hashimoto K. 2016. Brain-derived Neurotrophic Factor (BDNF)-TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol. 14:721–731.
  • Zhang K, Yang C, Xu Y, Sun N, Yang H, Liu J, Xu Q, Shen Y. 2010. Genetic association of the interaction between the BDNF and GSK3B genes and major depressive disorder in a Chinese population. J Neural Transm (Vienna). 117:393–401.
  • Zhang J-C, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li S-X, Shirayama Y, Hashimoto K. 2015. Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharm. 18:pyu077–7.
  • Zhu L, Nang C, Luo F, Pan H, Zhang K, Liu J, Zhou R, Gao J, Chang X, He H, et al. 2016. Esculetin attenuates lipopolysaccharide (LPS)-induced neuroinflammatory processes and depressive-like behavior in mice. Physiol Behav. 163:184–192.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.